Drug Interaction Report
2 potential interactions and/or warnings found for the following 2 drugs:
- talimogene laherparepvec
- Tasigna (nilotinib)
Interactions between your drugs
nilotinib talimogene laherparepvec
Applies to: Tasigna (nilotinib), talimogene laherparepvec
If you are currently being treated or have recently been treated with nilotinib, you should let your doctor know before receiving talimogene laherparepvec. Depending on the dose and length of time you have been on nilotinib, you may be at risk for developing a potentially life-threatening herpes infection from exposure to talimogene laherparepvec. In some situations, your doctor may want to delay treatment with talimogene laherparepvec to give your body time to recover from the effects of nilotinib therapy. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Drug and food/lifestyle interactions
nilotinib food/lifestyle
Applies to: Tasigna (nilotinib)
Do not consume grapefruit or grapefruit juice during treatment with nilotinib unless directed otherwise by your doctor. Grapefruit juice can increase the blood levels of nilotinib to dangerous levels, increasing the risk of an irregular heart rhythm that may be serious. You should seek immediate medical attention if you develop sudden dizziness, lightheadedness, fainting, shortness of breath, or heart palpitations during treatment with nilotinib. Food may also increase the blood levels of nilotinib. Therefore, you should take nilotinib on an empty stomach, meaning no food should be eaten for at least two hours before or one hour after taking nilotinib. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Opdivo
Opdivo is used to treat many cancers, such as melanoma, non-small cell lung cancer, malignant ...
Keytruda
Keytruda is used to treat melanoma, non-small cell lung cancer, malignant pleural mesothelioma ...
Botox
Botox is used cosmetically to reduce facial lines and wrinkles and for medical purposes for ...
Tafinlar
Tafinlar is a prescription medicine used to treat BRAF mutated melanoma, non-small cell lung ...
Mekinist
Mekinist is used to treat melanoma, non-small cell lung cancer, thyroid cancer, solid tumors, and ...
Yervoy
Yervoy (ipilimumab) is a cancer treatment used for lung cancer, melanoma, renal cell carcinoma ...
Ipilimumab
ipilimumab (Yervoy) is an immunotherapy used for melanoma, renal cell carcinoma, non-small cell ...
Dacarbazine
Dacarbazine is used for hodgkin's lymphoma, melanoma, melanoma, metastatic
Dabrafenib
Dabrafenib is used for low-grade glioma, melanoma, metastatic, non small cell lung cancer, solid ...
Trametinib
Trametinib is used for low-grade glioma, melanoma, metastatic, non small cell lung cancer, solid ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.